Browsing Tag
Neuren Pharmaceuticals Limited
4 posts
Neuren Pharmaceuticals (ASX: NEU) lifts 2026 royalty outlook after record DAYBUE quarter
Record DAYBUE sales and rapid adoption of its STIX formulation have strengthened Neuren Pharmaceuticals’ royalty outlook, while Europe and Japan offer the next major tests of the franchise’s global potential.
Neuren Pharmaceuticals (ASX: NEU) jumped 45% in two sessions, but how much DAYBUE upside remains?
DAYBUE’s EU breakthrough sent NEU up 45% in two sessions. The harder test is whether royalties and NNZ-2591 justify A$2.25 billion.
Neuren Pharmaceuticals (ASX: NEU) begins first-ever Phase 3 trial in Phelan-McDermid syndrome
Neuren Pharmaceuticals Limited has dosed the first patient in the first Phase 3 Phelan-McDermid syndrome trial. See why it matters for rare disease drug development.
ACADIA Pharmaceuticals stock surges 26% after key patent win and robust Q1 results: What’s driving investor optimism?
Find out why ACADIA Pharmaceuticals stock soared 26% on May 16, 2025, after a favorable court ruling and strong earnings—plus what’s next for its CNS pipeline.